Fluoxetine and the mitochondria: A review of the toxicological aspects

Toxicology Letters

Volumn 258, Issue , 2016, Pages 185-191

  de Oliveira, Marcos Roberto ^a  

^a FEDERAL UNIVERSITY OF MATO GROSSO   (Brazil)

Author keywords

Apoptosis; Fluoxetine; Mitochondria; Reactive oxygen species; Respiratory chain

Indexed keywords

FLUOXETINE; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

APOPTOSIS; CELL FUNCTION; DRUG EFFECT; EXPERIMENTAL MODEL; HUMAN; MAMMAL; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; ANIMAL; DRUG EFFECTS; DRUG INTERACTION; ELECTRON TRANSPORT; ENZYMOLOGY; METABOLISM; OXIDATIVE PHOSPHORYLATION; TOXICITY TESTING;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; APOPTOSIS; DRUG INTERACTIONS; ELECTRON TRANSPORT; FLUOXETINE; HUMANS; MITOCHONDRIA; OXIDATIVE PHOSPHORYLATION; SEROTONIN UPTAKE INHIBITORS; TOXICITY TESTS, ACUTE; TOXICITY TESTS, CHRONIC;

EID: 84982170345     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2016.07.001     Document Type: Short Survey

References (64)

1. Abdel-Razaq, W., Kendall, D.A., Bates, T.E., The effects of antidepressants on mitochondrial function in a model cell system and isolated mitochondria. Neurochem. Res. 36 (2011), 327–338.
2. Adzic, M., Lukic, I., Mitic, M., Djordjevic, J., Elaković, I., Djordjevic, A., Krstic-Demonacos, M., Matić, G., Radojcic, M., Brain region- and sex-specific modulation of mitochondrial glucocorticoid receptor phosphorylation in fluoxetine treated stressed rats: effects on energy metabolism. Psychoneuroendocrinology 38 (2013), 2914–2924.
3. Agostinho, F.R., Scaini, G., Ferreira, G.K., Jeremias, I.C., Réus, G.Z., Rezin, G.T., Castro, A.A., Zugno, A.I., Quevedo, J., Streck, E.L., Effects of olanzapine, fluoxetine and olanzapine/fluoxetine on creatine kinase activity in rat brain. Brain Res. Bull. 80 (2009), 337–340.
4. Agostinho, F.R., Réus, G.Z., Stringari, R.B., Ribeiro, K.F., Ferraro, A.K., Benedet, J., Rochi, N., Scaini, G., Streck, E.L., Quevedo, J., Treatment with olanzapine, fluoxetine and olanzapine/fluoxetine alters citrate synthase activity in rat brain. Neurosci. Lett. 487 (2011), 278–281.
5. Agostinho, F.R., Réus, G.Z., Stringari, R.B., Ribeiro, K.F., Ferreira, G.K., Jeremias, I.C., Scaini, G., Rezin, G.T., Streck, E.L., Quevedo, J., Olanzapine plus fluoxetine treatment alters mitochondrial respiratory chain activity in the rat brain. Acta Neuropsychiatr. 23 (2011), 282–291.
6. Bartholomä, P., Erlandsson, N., Kaufmann, K., Rössler, O.G., Baumann, B., Wirth, T., Giehl, K.M., Thiel, G., Neuronal cell death induced by antidepressants: lack of correlation with Egr-1, NF-kappa B and extracellular signal-regulated protein kinase activation. Biochem. Pharmacol. 63 (2002), 1507–1516.
7. Bernardi, P., Di Lisa, F., Fogolari, F., Lippe, G., From ATP to PTP and Back: a dual function for the mitochondrial ATP synthase. Circ. Res. 116 (2015), 1850–1862.
8. Brambilla, P., Cipriani, A., Hotopf, M., Barbui, C., Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry 38 (2005), 69–77.
9. Brandes, L.J., Arron, R.J., Bogdanovic, R.P., Tong, J., Zaborniak, C.L., Hogg, G.R., Warrington, R.C., Fang, W., LaBella, F.S., Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res. 52 (1992), 3796–3800.
10. Brown, G.C., Bal-Price, A., Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol. Neurobiol. 27 (2003), 325–355.
11. Cardoso, S., Carvalho, C., Marinho, R., Simões, A., Sena, C.M., Matafome, P., Santos, M.S., Seiça, R.M., Moreira, P.I., Effects of methylglyoxal and pyridoxamine in rat brain mitochondria bioenergetics and oxidative status. J. Bioenerg. Biomembr. 46 (2014), 347–355.
12. Coskun, P., Wyrembak, J., Schriner, S.E., Chen, H.W., Marciniack, C., Laferla, F., Wallace, D.C., A mitochondrial etiology of Alzheimer and Parkinson disease. Biochim. Biophys. Acta 1820 (2012), 553–564.
13. Cotterchio, M., Kreiger, N., Darlington, G., Steingart, A., Antidepressant medication use and breast cancer risk. Am. J. Epidemiol. 151 (2000), 951–957.
14. Curti, C., Mingatto, F.E., Polizello, A.C., Galastri, L.O., Uyemura, S.A., Santos, A.C., Fluoxetine interacts with the lipid bilayer of the inner membrane in isolated rat brain mitochondria, inhibiting electron transport and F1F0-ATPase activity. Mol. Cell. Biochem. 199 (1999), 103–109.
15. Daud, F.V., Murad, N., Meneghini, A., Ferreira, M., Ferreira Filho, C., Abreu, L.C., Valenti, V.E., Ferreira, C., Fluoxetine effects on mitochondrial ultrastructure of right ventricle in rats exposed to cold stress. Rev. Bras. Cir. Cardiovasc. 24 (2009), 173–179.
16. Deák, F., Lasztóczi, B., Pacher, P., Petheö, G.L., Kecskeméti, V., Spät, A., Inhibition of voltage-gated calcium channels by fluoxetine in rat hippocampal pyramidal cells. Neuropharmacology 39 (2000), 1029–1036.
17. Demonacos, C.V., Karayanni, N., Hatzoglou, E., Tsiriyiotis, C., Spandidos, D.A., Sekeris, C.E., Mitochondrial genes as sites of primary action of steroid hormones. Steroids 61 (1996), 226–232.
18. Denk, A., Wirth, T., Baumann, B., NF-kappaB transcription factors: critical regulators of hematopoiesis and neuronal survival. Cytokine Growth Factor Rev. 11 (2000), 303–320.
19. Djordjevic, A., Djordjevic, J., Elaković, I., Adzic, M., Matić, G., Radojcic, M.B., Effects of fluoxetine on plasticity and apoptosis evoked by chronic stress in rat prefrontal cortex. Eur. J. Pharmacol. 693 (2012), 37–44.
20. Djordjevic, A., Djordjevic, J., Elaković, I., Adzic, M., Matić, G., Radojcic, M.B., Fluoxetine affects hippocampal plasticity, apoptosis and depressive-like behavior of chronically isolated rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 36 (2012), 92–100.
21. Fernández-Checa, J.C., García-Ruiz, C., Colell, A., Morales, A., Marí, M., Miranda, M., Ardite, E., Oxidative stress: role of mitochondria and protection by glutathione. Biofactors 8 (1998), 7–11.
22. Fuller, R.W., Wong, D.T., Robertson, D.W., Fluoxetine, a selective inhibitor of serotonin uptake. Med. Res. Rev. 11 (1991), 17–34.
23. García-Colunga, J., Awad, J.N., Miledi, R., Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 2041–2044.
24. Gough, D.R., Cotter, T.G., Hydrogen peroxide: a Jekyll and Hyde signalling molecule. Cell. Death. Dis., 2, 2011, e213.
25. Green, D.R., Galluzzi, L., Kroemer, G., Metabolic control of cell death. Science, 345, 2014, 1250256.
26. Halliwell, B., Oxidative stress and neurodegeneration: where are we now?. J. Neurochem 97 (2006), 1634–1658.
27. Han, Y.S., Lee, C.S., Antidepressants reveal differential effect against 1-methyl-4-phenylpyridinium toxicity in differentiated PC12 cells. Eur. J. Pharmacol. 604 (2009), 36–44.
28. Hroudová, J., Fišar, Z., In vitro inhibition of mitochondrial respiratory rate by antidepressants. Toxicol. Lett. 213 (2012), 345–352.
29. Jang, Y., Lee, A.Y., Jeong, S.H., Park, K.H., Paik, M.K., Cho, N.J., Kim, J.E., Cho, M.H., Chlorpyrifos induces NLRP3 inflammasome and pyroptosis/apoptosis via mitochondrial oxidative stress in human keratinocyte HaCaT cells. Toxicology 338 (2015), 37–46.
30. Kasote, D.M., Hegde, M.V., Katyare, S.S., Mitochondrial dysfunction in psychiatric and neurological diseases: cause(s), consequence(s), and implications of antioxidant therapy. Biofactors 39 (2013), 392–406.
31. Lee, C.S., Kim, Y.J., Jang, E.R., Kim, W., Myung, S.C., Fluoxetine induces apoptosis in ovarian carcinoma cell line OVCAR-3 through reactive oxygen species-dependent activation of nuclear factor-kappaB. Basic Clin. Pharmacol. Toxicol. 106 (2010), 446–453.
32. Leonardi, E.T., Azmitia, E.C., MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 10 (1994), 231–238.
33. Manoli, I., Alesci, S., Blackman, M.R., Su, Y.A., Rennert, O.M., Chrousos, G.P., Mitochondria as key components of the stress response. Trends Endocrinol. Metab. 18 (2007), 190–198.
34. Marí, M., Morales, A., Colell, A., García-Ruiz, C., Fernández-Checa, J.C., Mitochondrial glutathione, a key survival antioxidant. Antioxid. Redox Signal. 11 (2009), 2685–2700.
35. Marín-García, J., Akhmedov, A.T., Mitochondrial dynamics and cell death in heart failure. Heart Fail. Rev. 21 (2016), 123–136.
36. Martin, S.D., McGee, S.L., The role of mitochondria in the aetiology of insulin resistance and type 2 diabetes. Biochim. Biophys. Acta 1840 (2014), 1303–1312.
37. Mattson, M.P., Culmsee, C., Yu, Z., Camandola, S., Roles of nuclear factor kappaB in neuronal survival and plasticity. J. Neurochem. 74 (2000), 443–456.
38. Mukherjee, J., Das, M.K., Yang, Z.Y., Lew, R., Evaluation of the binding of the radiolabeled antidepressant drug, 18F-fluoxetine in the rodent brain: an in vitro and in vivo study. Nucl. Med. Biol. 25 (1998), 605–610.
39. Nahon, E., Israelson, A., Abu-Hamad, S., Varda, S.B., Fluoxetine (Prozac) interaction with the mitochondrial voltage-dependent anion channel and protection against apoptotic cell death. FEBS Lett. 579 (2005), 5105–5110.
40. Naoi, M., Maruyama, W., Shamoto-Nagai, M., Yi, H., Akao, Y., Tanaka, M., Oxidative stress in mitochondria: decision to survival and death of neurons in neurodegenerative disorders. Mol. Neurobiol. 31 (2005), 81–93.
41. Nicholls, D.G., Budd, S.L., Neuronal excitotoxicity: the role of mitochondria. Biofactors 8 (1998), 287–299.
42. Pancrazio, J.J., Kamatchi, G.L., Roscoe, A.K., Lynch, C. 3rd, Inhibition of neuronal Na+ channels by antidepressant drugs. J. Pharmacol. 284 (1998), 208–214.
43. Peer, D., Dekel, Y., Melikhov, D., Margalit, R., Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res. 64 (2004), 7562–7569.
44. Post, A., Crochemore, C., Uhr, M., Holsboer, F., Behl, C., Differential induction of NF-kappaB activity and neural cell death by antidepressants in vitro. Eur. J. Neurosci. 12 (2000), 4331–4337.
45. Qin, Z.H., Tao, L.Y., Chen, X., Dual roles of NF-kappaB in cell survival and implications of NF-kappaB inhibitors in neuroprotective therapy. Acta Pharmacol. Sin. 28 (2007), 1859–1872.
46. Ribas, V., García-Ruiz, C., Fernández-Checa, J.C., Glutathione and mitochondria. Front. Pharmacol., 5, 2014, 151.
47. Russell, A.P., Foletta, V.C., Snow, R.J., Wadley, G.D., Skeletal muscle mitochondria: a major player in exercise, health and disease. Biochim. Biophys. Acta 1840 (2014), 1276–1284.
48. Sarnico, I., Lanzillotta, A., Benarese, M., Alghisi, M., Baiguera, C., Battistin, L., Spano, P., Pizzi, M., NF-kappaB dimers in the regulation of neuronal survival. Int. Rev. Neurobiol. 85 (2009), 351–362.
49. Schneider, A., Martin-Villalba, A., Weih, F., Vogel, J., Wirth, T., Schwaninger, M., NF-kappaB is activated and promotes cell death in focal cerebral ischemia. Nat. Med. 5 (1999), 554–559.
50. Serafeim, A., Holder, M.J., Grafton, G., Chamba, A., Drayson, M.T., Luong, Q.T., Bunce, C.M., Gregory, C.D., Barnes, N.M., Gordon, J., Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 101 (2003), 3212–3219.
51. Souza, M.E., Polizello, A.C., Uyemura, S.A., Castro-Silva, O., Curti, C., Effect of fluoxetine on rat liver mitochondria. Biochem. Pharmacol. 48 (1994), 535–541.
52. Stone, J.R., Yang, S., Hydrogen peroxide: a signaling messenger. Antioxid. Redox Signal. 8 (2006), 243–270.
53. Swerdlow, R.H., Alzheimer's disease pathologic cascades: who comes first, what drives what. Neurotox. Res. 22 (2012), 182–194.
54. Tajeddine, N., How do reactive oxygen species and calcium trigger mitochondrial membrane permeabilisation?. Biochim. Biophys. Acta 1860 (2016), 1079–1088.
55. Thinnes, F.P., Does fluoxetine (Prozak) block mitochondrial permeability transition by blocking VDAC as part of permeability transition pores?. Mol. Genet. Metab., 84, 2005, 378.
56. Veal, E.A., Day, A.M., Morgan, B.A., Hydrogen peroxide sensing and signaling. Mol. Cell 26 (2007), 1–114.
57. Walters, J.W., Amos, D., Ray, K., Santanam, N., Mitochondrial redox status as a target for cardiovascular disease. Curr. Opin. Pharmacol. 27 (2016), 50–55.
58. Wang, P.S., Walker, A.M., Tsuang, M.T., Orav, E.J., Levin, R., Avorn, J., Antidepressant use and the risk of breast cancer: a non-association. J. Clin. Epidemiol. 54 (2001), 728–734.
59. Wang, W., Karamanlidis, G., Tian, R., Novel targets for mitochondrial medicine. Sci. Transl. Med., 8, 2016, 326rv3.
60. Wen, L., Jin, Y., Li, L., Sun, S., Cheng, S., Zhang, S., Zhang, Y., Svenningsson, P., Exercise prevents raphe nucleus mitochondrial overactivity in a rat depression model. Physiol. Behav. 132 (2014), 57–65.
61. Wright, S.C., Zhong, J., Larrick, J.W., Inhibition of apoptosis as a mechanism of tumor promotion. FASEB J. 8 (1994), 654–660.
62. de Oliveira, M.R., Ferreira, G.C., Schuck, P.F., Dal Bosco, S.M., Role for the PI3K/Akt/Nrf2 signaling pathway in the protective effects of carnosic acid against methylglyoxal-induced neurotoxicity in SH-SY5Y neuroblastoma cells. Chem. Biol. Interact. 242 (2015), 396–406.
63. de Oliveira, M.R., Nabavi, S.F., Habtemariam, S., Orhan, I.E., Daglia, M., Nabavi, S.M., The effects of baicalein and baicalin on mitochondrial function and dynamics. A review. Pharmacol. Res. 100 (2015), 296–308.
64. de Oliveira, M.R., Ferreira, G.C., Schuck, P.F., Protective effect of carnosic acid against paraquat-induced redox impairment and mitochondrial dysfunction in SH-SY5Y cells: role for PI3K/Akt/Nrf2 pathway. Toxicol. In Vitro 32 (2016), 41–54.